Free tool
FAERS Monitor: Iluvien
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201923 or its brand name (Iluvien, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
2,447
Serious
1,130
46% of reports
Hospitalization
325
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective197
- intraocular pressure increased192
- off label use169
- pruritus166
- rash144
- diarrhoea115
- device failure111
- psoriasis95
- device dislocation92
- headache90
- fatigue89
- circumstance or information capable of leading to medication error87
- pain85
- nausea82
- condition aggravated81
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 14 |
| 2006 | 7 |
| 2007 | 11 |
| 2008 | 9 |
| 2009 | 15 |
| 2010 | 17 |
| 2011 | 28 |
| 2012 | 32 |
| 2013 | 17 |
| 2014 | 26 |
| 2015 | 54 |
| 2016 | 84 |
| 2017 | 95 |
| 2018 | 103 |
| 2019 | 267 |
| 2020 | 159 |
| 2021 | 193 |
| 2022 | 248 |
| 2023 | 225 |
| 2024 | 277 |
| 2025 | 356 |
| 2026 | 202 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 192 | 131.1 | 114.3 | 24,300 |
| device failureSignal | 111 | 63.1 | 52.6 | 6,679 |
| circumstance or information capable of leading to medication errorSignal | 87 | 22.2 | 18.1 | 1,738 |
| device dislocationSignal | 92 | 18.2 | 14.9 | 1,480 |
| psoriasisSignal | 95 | 6.3 | 5.1 | 417 |
| pruritusSignal | 166 | 3.7 | 3.2 | 332 |
| rashSignal | 144 | 2.8 | 2.4 | 173 |
| condition aggravatedSignal | 81 | 2.3 | 1.8 | 58 |
| off label use | 169 | 1.7 | 1.4 | 45 |
| diarrhoea | 115 | 1.5 | 1.3 | 21 |
| drug ineffective | 197 | 1.3 | 1.1 | 13 |
| headache | 90 | 1.2 | 1.0 | 4 |
| pain | 85 | 1.2 | 1.0 | 2 |
| fatigue | 89 | 1.0 | 0.8 | 0 |
| nausea | 82 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.